X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian stock markets lose ground 
(Mon, 26 Aug 01:30 pm) 
 
Indian stock markets pared gains in last two hours of trade and are trading below the dotted line. Sectoral indices are trading mixed. Stocks from metal and IT are among leading gainers while banking and oil and gas stocks are leading the losses.

BSE-Sensex is down by 4 points and NSE-Nifty is trading up by 8 points. While BSE Mid Cap is trading up by 0.50%, BSE Small Cap index is trading up by 0.77%. The rupee is trading at 64.11 to the US dollar.

Majority of PSU banking stocks are trading in green, with Syndicate bank and Indian bank witnessing maximum buying interest. As per a financial daily, The Reserve Bank of India (RBI) on Friday penalized six PSU banks for violating know-your-customer (KYC) and anti- money laundering (AML) norms. The six PSU banks viz; Allahabad bank, Bank of Maharashtra, Corporation bank, IDBI bank,Dena bank and Indian bank were penalized by the RBI. The penalties on these banks ranged from 50 lakh to 2 crore. Apart from violating KYC and AML norms, the banks have also been found to have sold gold coins for cash of beyond 50,000. This is in non-adherence to instructions on import of gold on consignment basis. Various violating activities included not following KYC norms for walk-in customers in sale of third-party products and omitting filing of cash transaction with respect to certain transactions.

Most of the Indian pharma Stocks are trading in green, with Elder pharmaceuticals and Wockhart Ltd leading the gainers. Lupin Ltd has announced that it has received final approval for Rifampin capsules USP for 150mg and 300mg strengths from the United States Food and Drugs Administration (USFDA). The said drug is equivalent to Rifadin capsules. Rifadin brand is marketed by Sanofi Aventis, a France based company. Rifampin is indicated for the treatment of tuberculosis (TB), and for the treatment of asymptomatic carriers of Neisseria meningitides. Rifadin Capsules brand had annual U.S sales of $ 18.5 m. Lupin is one of the pioneers in the tuberculosis drugs market and holds global leadership position in the anti-TB segment. Lupin was trading down by 2.16%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian stock markets lose ground". Click here!

  
 

S&P BSE SENSEX


Apr 26, 2017 03:15 PM

S&P BSE SENSEX 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS